In the latest research, Covaxin’s Covid 19 dose which is developed by Bharat Biotech is said to be generating antibodies that can neutralise the Alpha and Delta variants of SARS-CoV-2. The US National Institutes of Health reported the same from the two studies of blood serum of the people who took the jab.
Vaccine Adjuvant Used In Covaxin Boosts Immune Responses
As per the latest reports released by the NIH states that an adjuvant developed by the agency has contributed to the high effectiveness of the Covaxin Covid 19 vaccine. The vaccine has been administered to roughly 25 million people across the world.
Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.
ALSO READ: Covishield, Covaxin Work Against Alpha-Beta-Gamma-Delta Variants: DG-ICMR
Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases who is the part of NIH said that to end a global pandemic, we need a global response. He further said that they are pleased to know that a novel vaccine adjuvant developed in the US with NIAID’s support is available in India.
The adjuvant used in Covaxin — Alhydroxiquim-II — was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Programme.
The adjuvant has a small molecule attached in a unique way to Alhydrogel, a substance that is generally found in alum which is very commonly used in vaccines for people.
Phase 2 Trials Of Covaxin Indicate Safety and Well Tolerance
Reports suggest that the Alhydroxiquim-II travels to lymph nodes, where the small molecule detaches from alum and activates two cellular receptors. These receptors, TLR7 and TLR8, play a vital role in the immune response to viruses.
Since the Covaxin is injected to the person, the adjuvant travels directly to lymph nodes which carries the white blood cells that plan a crucial role in identifying pathogens and fight against the infection.
Results from the Phase 2 trials of Covaxin indicate that the vaccines are safe and well-tolerated by the people. Furthermore, the interim results from phase 3 suggest that the vaccine has 78 percent efficacy against the symptomatic disease. It shows 100 percent efficacy against severe Covid 19 and 70 percent efficacy against asymptomatic infection.
